nach oben

Current Oncology Reports

Erschienen in:

01.01.2021 | Geriatric Oncology (L Balducci, Section Editor)

The Role of Radiation Therapy in the Older Patient

verfasst von: Ammoren Dohm, Roberto Diaz, Ronica H. Nanda

Erschienen in: Current Oncology Reports | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Older patients represent a unique subgroup of the cancer patient population for which the role of radiation therapy (RT) requires special consideration. This review will discuss many of these considerations as well as various radiation treatment techniques in the context of a variety of disease sites.

Recent Findings

Several recent studies give insight into the management of older cancer patients considering their age, performance status, comorbid conditions, quality of life, genetics, cost, and individual goals. RT plays an evolving and pivotal role in providing optimal care for this population. Recent advances in RT technique allow for more precise treatment delivery and reduced toxicity. Studies evaluating the use of radiation therapy in breast, brain, lung, prostate, rectal, pancreatic, esophageal, and oligometastatic cancer are summarized and discussed in the context of treating the older patient population.

Summary

Individual age, performance and functional status, comorbid conditions, and patients’ objectives and goals should all be considered when presenting treatment options for older patients and age alone should not disqualify patients from curative intent treatments. When possible, hypofractionated courses should be utilized as outcomes are often equivalent and toxicities are reduced. In many cases, RT may be preferable to other treatment options due to decreased toxicity profile and acceptable disease control.

Browner I. Applications in geriatric oncology [Internet]. 2017 [cited 2020 May 1]. Available from: https://www.hopkinsmedicine.org/gec/series/cancer_aging.html. Accessed 1 May 2020.

Kochanek KD, Murphy SL, Xu J, Arias E. Deaths: final data for 2017. 2019; Available from: https://stacks.cdc.gov/view/cdc/79486. Accessed 17 Aug 2020.

Lutz ST, Jones J, Chow E. Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol. 2014;32:2913–9.PubMedPubMedCentralCrossRef

Peck A, Boland J. Emotional reactions to radiation treatment. Cancer. 1977;40:180–4.PubMedCrossRef

Alteri R, Bandi P, Brinton L, Casares C, Cokkinides V, Gansler T, et al. Breast cancer facts & figures 2011--2012. Am Cancer Soc. 2011:1–36.

Altekruse SF, Kosary CL, Krapcho M, et al. Surveillance, epidemiology, and end results cancer statistics review, 1975-2007. Bethesda: National Cancer Institute; 2010.

Beadle BM, Woodward WA, Buchholz TA. The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol. 2011;21:26–34.PubMedPubMedCentralCrossRef

8.•

Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7:347–50 This is a discussion of the TAILORx trial and its use in clinical decision-making, specifically the use of molecular diagnostic testing to identify patients who would benefit from chemotherapy.PubMedCrossRef

Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729–35.PubMedCrossRef

10.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMedCrossRef

11.

Mogal HD, Clark C, Dodson R, Fino NF, Howard-McNatt M. Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol. 2017;24:100–7.PubMedCrossRef

12.

NCCN Clinical practice guidelines in oncology [Internet]. [cited 2020 May 20]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 20 May 2020.

13.

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRef

14.

Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006;24:4901–7.PubMedCrossRef

15. ••

Shirvani SM, Pan I-W, Buchholz TA, Shih Y-CT, Hoffman KE, Giordano SH, et al. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer. 2011;117:4595–605 This paper uses SEER data to show that, in women ≥ 66 years who underwent mastectomy, a large number with high-risk disease did not receive post-mastectomy radiation therapy (PMRT) despite guideline changes to do so. In fact, only 54.8% of high-risk patients evaluated between 1999 and 2005 received PMRT.

16.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.PubMedCrossRef

17.

Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx. J Clin Oncol. 2020:JCO1901866.

18.

Dispinzieri M, La Rocca E, Meneghini E, Fiorentino A, Lozza L, Di Cosimo S, et al. Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. Med Oncol. 2018;35:107.PubMedCrossRef

19.

Broman K, Sun W, Zhou J-M, Fridley B, Diaz R, Laronga C. Outcomes of selective whole breast irradiation following lumpectomy with intraoperative radiation therapy for hormone receptor positive breast cancer. Am J Surg. 2019;218:749–54.PubMedPubMedCentralCrossRef

20.•

Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8 This paper reviews adherence to hormone therapy for women with hormone-sensitive breast cancer. Younger or older age, lumpectomy (versus mastectomy), and comorbidities were associated with earlier discontinuation. By 4.5 years, 32% discontinued therapy.PubMedPubMedCentralCrossRef

21.

Bhattacharya IS, Haviland JS, Kirby AM, Kirwan CC, Hopwood P, Yarnold JR, et al. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial [Internet]. J Clin Oncol. 2019:305–17. Available from. https://doi.org/10.1200/jco.18.00982.

22.

Brownlee Z, Garg R, Listo M, Zavitsanos P, Wazer DE, Huber KE. Late complications of radiation therapy for breast cancer: evolution in techniques and risk over time. Gland Surg. 2018;7:371–8.PubMedPubMedCentralCrossRef

23.

Buszek SM, Lin HY, Bedrosian I, Tamirisa N, Babiera GV, Shen Y, et al. Lumpectomy plus hormone or radiation therapy alone for women aged 70 years or older with hormone receptor–positive early stage breast cancer in the modern era: an analysis of the National Cancer Database [Internet]. Int J Radiat Oncol Biol Phys. 2019:795–802. Available from. https://doi.org/10.1016/j.ijrobp.2019.07.052.

24.

Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17:154–70.PubMedCrossRef

25.

Kirby AM. Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial? Br J Radiol. 2018;91:20170565.PubMedPubMedCentralCrossRef

26.

Sumodhee S, Levy J, Chamorey E, Lam Cham Kee D, Chand M-E, Gautier M, et al. Accelerated partial breast irradiation for elderly women with early breast cancer: a compromise between whole breast irradiation and omission of radiotherapy. Brachytherapy. 2017;16:929–34.PubMedCrossRef

27.

Dragun AE. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite® Breast Brachytherapy Registry trial [Internet]: Breast Diseases: A Year Book Quarterly; 2014. p. 77–8. Available from:. https://doi.org/10.1016/j.breastdis.2014.01.021. Accessed 14 July 2020.

28.

Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13.PubMedCrossRef

29.

Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77.PubMedCrossRef

30.

Neumaier C, Elena S, Grit W, Yasser A-M, Uta K-T, Anke K, et al. TARGIT-E(lderly)—Prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. BMC Cancer. 2012;12:171.PubMedPubMedCentralCrossRef

31.

Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin. 2003;53:227–44.PubMedCrossRef

32.

Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597–605.PubMedCrossRef

33.

Daugherty EC, Daugherty MR, Bogart JA, Shapiro A. Adjuvant radiation improves survival in older women following breast-conserving surgery for estrogen receptor–negative breast cancer. Clin Breast Cancer. 2016;16:500–6.e2.PubMedCrossRef

34.

Haque W, Kee Yuan DM, Verma V, Butler EB, Teh BS, Wiederhold L, et al. Radiation therapy utilization and outcomes for older women with breast cancer: Impact of molecular subtype and tumor grade. Breast. 2017;35:34–41.PubMedCrossRef

35.

Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144:1251–61.PubMedCrossRef

36.

de Kruijf EM, Bastiaannet E, Rubertá F, de Craen AJM, Kuppen PJK, Smit VTHBM, et al. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. Mol Oncol. 2014;8:1014–25.PubMedPubMedCentralCrossRef

37.

Engels CC, Kiderlen M, Bastiaannet E, Mooyaart AL, van Vlierberghe R, Smit VTHBM, et al. The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: a FOCUS study analysis. Mol Oncol. 2016;10:594–600.PubMedCrossRef

38.

Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, et al. A significant proportion of elderly patients develop hormone-dependant “luminal-B” tumours associated with aggressive characteristics. Crit Rev Oncol Hematol. 2008;67:80–92.PubMedCrossRef

39.

Coles CE. Patient reported outcomes over 5 years following whole or partial breast radiotherapy: longitudinal analysis of the IMPORT LOW phase III randomised controlled trial. Proc Am Soc Clin Oncol. 2019; Available from: https://www.repository.cam.ac.uk/handle/1810/288038. Accessed 14 July 2020.

40.

Badakhshi H, Gruen A, Sehouli J, Budach V, Boehmer D. The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study. Cancer Med. 2013;2:712–7.PubMedPubMedCentralCrossRef

41.

Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017;135:1388–96.PubMedPubMedCentralCrossRef

42.

Marks L, Constine LS, Adams J, Schild SE. Cardiotoxicity of radiation therapy for breast cancer and other malignancies. UpToDate [Internet]. 2017; Available from: https://www.uptodate.com/contents/cardiotoxicity-of-radiation-therapy-for-breast-cancer-and-other-malignancies. Accessed 11 Aug 2020.

43.

Shumway DA, Griffith KA, Sabel MS, Jones RD, Forstner JM, Bott-Kothari TL, et al. Surgeon and radiation oncologist views on omission of adjuvant radiotherapy for older women with early-stage breast cancer. Ann Surg Oncol. 2017;24:3518–26.PubMedCrossRef

44.

Hamelinck VC, Stiggelbout AM, van de Velde CJH, Liefers G-J, Bastiaannet E. Treatment recommendations for older women with breast cancer: a survey among surgical, radiation and medical oncologists. Eur J Surg Oncol. 2017;43:1288–96.PubMedCrossRef

45.

Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol Oxford Academic. 2019;21:v1–100.CrossRef

46.

Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiotherapy of benign meningioma in the elderly: clinical outcome and toxicity in 121 patients. Radiother Oncol. 2014;111:457–62.PubMedCrossRef

47.

Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H, et al. Prognostic factors derived from recursive partition analysis (RPA) of radiation therapy oncology group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases [Internet]. Int J Radiat Oncol Biol Phys. 1998:155–9. Available from:. https://doi.org/10.1016/s0360-3016(98)00198-9.

48.

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–25.PubMedCrossRef

49.•

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401–9 This clinical trial evaluated the cognitive function of patients treated with either SRS alone or SRS with WBRT. There were 213 randomized participants. Less cognitive deterioration at 3 months after SRS alone than when combined with WBRT (difference, − 28.2%; 90% CI, − 41.9 to − 14.4%; p < 0.001). No difference was seen in overall survival.PubMedPubMedCentralCrossRef

50.

Noel G, Bollet MA, Noel S, Feuvret L, Boisserie G, Tep B, et al. Linac stereotactic radiosurgery: an effective and safe treatment for elderly patients with brain metastases. Int J Radiat Oncol Biol Phys. 2005;63:1555–61.PubMedCrossRef

51.

Kim S-H, Weil RJ, Chao ST, Toms SA, Angelov L, Vogelbaum MA, et al. Stereotactic radiosurgical treatment of brain metastases in older patients. Cancer. 2008;113:834–40.PubMedCrossRef

52.

Minniti G, Esposito V, Clarke E, Scaringi C, Bozzao A, Lanzetta G, et al. Stereotactic radiosurgery in elderly patients with brain metastases. J Neuro-Oncol. 2013;111:319–25.CrossRef

53.

Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. J Clin Oncol. 2020;38:1019–29.PubMedPubMedCentralCrossRef

54.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–91.PubMedCrossRef

55.

DeAngelis LM. Whither whole brain radiotherapy for primary CNS lymphoma? Neuro-Oncology. 2014;16:1032–4.PubMedPubMedCentralCrossRef

56.

Omuro AMP, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595–600.PubMedCrossRef

57.

Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-Oncology. 2012;14:101–8.PubMedCrossRef

58.

Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570–4.PubMedCrossRef

59.

Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology. 2005;64:1184–8.PubMedCrossRef

60.

Rubenstein JL, Hsi ED, Johnson JL, Jung S-H, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–8.PubMedPubMedCentralCrossRef

61.

Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008;26:2512–8.PubMedCrossRef

62.

Correa DD, Rocco-Donovan M, DeAngelis LM, Dolgoff-Kaspar R, Iwamoto F, Yahalom J, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neuro-Oncol. 2009;91:315–21.CrossRef

63.

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971–9.PubMedPubMedCentralCrossRef

64.

Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, et al. Association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma [Internet]. JAMA Oncol. 2020:495. Available from:. https://doi.org/10.1001/jamaoncol.2019.6143.

65.

Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628–34.PubMedCrossRef

66.

Hoffermann M, Bruckmann L, Kariem Mahdy A, Asslaber M, Payer F, von Campe G. Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis. Clin Neurol Neurosurg. 2015;128:60–9.PubMedCrossRef

67.

Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol Springer. 2009;64:769.CrossRef

68.

Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–8.PubMedCrossRef

69.

Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neuro-Oncol. 2012;107:395–405.CrossRef

70.•

Lu VM, Kerezoudis P, Brown DA, Burns TC, Quinones-Hinojosa A, Chaichana KL. Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. J Neuro-Oncol. 2019;143:177–85 This meta-analysis compared elderly patients treated with hypofractionated RT (hRT) + temozolomide vs standard fractionation + temozolomide. They found that the hypofractionation had similar progression-free survival but a decreased overall survival. The authors suggest the combination of hRT + TMZ is feasible in well-selected elderly GBM cases.CrossRef

71.

Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, et al. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015;92:384–9.PubMedCrossRef

72.

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131:1342–50.PubMedCrossRef

73.••

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26 This phase 3 trial evaluated the optimum palliative treatment glioblastoma as described in the study title. Overall survival was similar between TMZ and hRT. For age 70 or older, survival was better with TMZ and with hRT than with standard RT (HR for TMZ vs standard RT 0.35 [0.21–0.56], p < 0.0001; HR for hRT vs standard RT 0.59 [95% CI 0.37–0.93], p = 0·02). Patients treated with TMZ who had MGMT promoter methylation had longer survival than those without (p = 0.02).PubMedCrossRef

74.

Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35.PubMedCrossRef

75.••

Atagi S, Mizusawa J, Ishikura S, Takahashi T, Okamoto H, Tanaka H, et al. Chemoradiotherapy in elderly patients with non-small-cell lung cancer: long-term follow-up of a randomized trial (JCOG0301). Clin Lung Cancer. 2018;19:e619–27 This phase III trial evaluated patients > 70 with stage III NSCLC and randomized them to chemoradiotherapy (CRT) or RT. CRT arm had better overall survival than the RT arm (p = 0.0239).PubMedCrossRef

76.

Dalwadi SM, Savjani RR, Bernicker EH, Butler EB, Teh BS, Farach AM. A matter of comprehensive informed consent: short-term mortality rates with definitive treatment options in elderly stage I NSCLC. Am J Clin Oncol. 2019;42:851–5.PubMedCrossRef

77.

Lee K, Kim HO, Choi HK, Seo GH. Real-world treatment patterns for patients 80 years and older with early lung cancer: a nationwide claims study. BMC Pulm Med. 2018;18:127.PubMedPubMedCentralCrossRef

78.•

Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, et al. Efficacy and toxicity analysis of NRG Oncology/RTOG 0813 Trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys Elsevier. 2016;96:S8 This paper evaluates phase II results of NRG/RTOG 0813 evaluating the use of SBRT for T1–2 (< 5 cm) N0M0 centrally located NSCLC in 71 patients treated in either a 12Gy/fraction or 11.5 Gy/fraction cohort. Late toxicities grade 3 or greater attributed to SBRT were acceptable. Two-year overall survival was 70%.CrossRef

79.

Videtic GM, Suescun JAG, Stephans KL, Bogart JA, Tian L, Groman A, et al. A phase 2 randomized study of 2 stereotactic body radiation therapy (SBRT) regimens for medically inoperable patients with node-negative, peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys Elsevier. 2016;96:S8–9.CrossRef

80.

Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.PubMedPubMedCentralCrossRef

81.

Nanda RH, Liu Y, Gillespie TW, Mikell JL, Ramalingam SS, Fernandez FG, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis. Cancer. 2015;121:4222–30.PubMedCrossRef

82.•

Cassidy RJ, Patel PR, Zhang X, Press RH, Switchenko JM, Pillai RN, et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients 80 years and older: a multi-center analysis. Clin Lung Cancer. 2017;18:551–8.e6 This multicenter study investigated the efficacy, safety, and survival of patients ≥ 80 years old with NSCLC treated with definitive lung SBRT. The study found that definitive lung SBRT for early-stage non-small-cell lung cancer was efficacious and safe in patients ≥ 80 years old. Patients with a KPS of ≥ 75 derived the most benefit from therapy.PubMedPubMedCentralCrossRef

83.

Cassidy RJ, Zhang X, Switchenko JM, Patel PR, Shelton JW, Tian S, et al. Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer. 2018;124:775–84.PubMedCrossRef

84.

Soni PD, Boonstra PS, Schipper MJ, Bazzi L, Dess RT, Matuszak MM, et al. Lower incidence of esophagitis in the elderly undergoing definitive radiation therapy for lung cancer. J Thorac Oncol. 2017;12:539–46.PubMedPubMedCentralCrossRef

85.

Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, et al. Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol. 2018;13:196.PubMedPubMedCentralCrossRef

86.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U. How do elderly poor prognosis patients tolerate palliative concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer stage III? A subset analysis from a clinical phase III trial. Clin Lung Cancer. 2015;16:183–92.PubMedCrossRef

87.

Vellekoop A, Loeb S. More aggressive prostate cancer in elderly men. Rev Urol. 2013;15:202–4.PubMedPubMedCentral

88.

Loeb S, Ross AE. Genomic testing for localized prostate cancer: where do we go from here? Curr Opin Urol. 2017;27:495–9.PubMedPubMedCentralCrossRef

89.

Daskivich TJ, Fan K-H, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. Urology. 2015;85:92–100.PubMedCrossRef

90.

Mandel P, Chandrasekar T, Chun F, Huland H, Tilki D. Radical prostatectomy in patients aged 75 years or older: review of the literature [Internet]. Asian J Androl. 2019:32. Available from:. https://doi.org/10.4103/aja.aja_43_17.

91.

Kundu SD, Roehl KA, Eggener SE, Antenor JAV, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172:2227–31.PubMedCrossRef

92.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–24.PubMedCrossRef

93.

Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884–90.PubMedCrossRef

94.

Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018;8:354–60.PubMedCrossRef

95.

Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97:976–85.PubMedCrossRef

96.

Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU. Image-guided radiotherapy for prostate cancer. Transl Androl Urol. 2018;7:308–20.PubMedPubMedCentralCrossRef

97.

Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2:e188006.PubMedPubMedCentralCrossRef

98.

Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007;246:215–21.PubMedPubMedCentralCrossRef

99.

Jung B, Påhlman L, Johansson R, Nilsson E. Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995-2004. BMC Cancer. 2009;9:68.PubMedPubMedCentralCrossRef

100.

Choi Y, Kim JH, Kim J-W, Kim JW, Lee K-W, Oh H-K, et al. Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study. Jpn J Clin Oncol. 2016;46:1108–17.PubMedCrossRef

101.

François E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, et al. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol. 2014;110:144–9.PubMedCrossRef

102.

Shahir MA, Lemmens VEPP, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen MLG. Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer. 2006;42:3015–21.PubMedCrossRef

103.

Maas HAAM, Lemmens VEPP, Nijhuis PHA, de Hingh IHJT, Koning CCE, Janssen-Heijnen MLG. Benefits and drawbacks of short-course preoperative radiotherapy in rectal cancer patients aged 75 years and older. Eur J Surg Oncol. 2013;39:1087–93.PubMedCrossRef

104.

Gani C, Kirschniak A, Zips D. Watchful waiting after radiochemotherapy in rectal cancer: when is it feasible? Visc Med. 2019;35:119–23.PubMedPubMedCentralCrossRef

105.

Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JCR, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.PubMedCrossRef

106.

Higuera O. Management of pancreatic cancer in the elderly [Internet]. World J Gastroenterol. 2016:764. Available from:. https://doi.org/10.3748/wjg.v22.i2.764.

107.

Hayman TJ, Strom T, Springett GM, Balducci L, Hoffe SE, Meredith KL, et al. Outcomes of resected pancreatic cancer in patients age ≥70. J Gastrointest Oncol. 2015;6:498–504.PubMedPubMedCentral

108.

Nagrial AM, Chang DK, Nguyen NQ, Johns AL, Chantrill LA, Humphris JL, et al. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer. 2014;110:313–9.PubMedCrossRef

109.

Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys Elsevier. 2011;80:1391–7.CrossRef

110.

Frakes J, Mellon EA, Springett GM, Hodul P, Malafa MP, Fulp WJ, et al. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. J Gastrointest Oncol. 2017;8:758–65.PubMedPubMedCentralCrossRef

111.

Morizane C, Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, et al. Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients. Oncology. 2005;68:432–7.PubMedCrossRef

112.

Miyamoto DT, Mamon HJ, Ryan DP, Willett CG, Ancukiewicz M, Kobayashi WK, et al. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys. 2010;77:1171–7.PubMedCrossRef

113.

de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123:4158–67.PubMedCrossRef

114.

Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123:3486–93.PubMedCrossRef

115.

Sutera PA, Bernard ME, Wang H, Heron DE. Prognostic factors for elderly patients treated with stereotactic body radiation therapy for pancreatic adenocarcinoma. Front Oncol. 2018;8:282.PubMedPubMedCentralCrossRef

116.

Jiang W, Haque W, Verma V, Butler EB, Teh BS. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. Acta Oncol. 2019;58:1259–66.PubMedCrossRef

117.

Yechieli RL, Robbins JR, Mahan M, Siddiqui F, Ajlouni M. Stereotactic body radiotherapy for elderly patients with medically inoperable pancreatic cancer. Am J Clin Oncol. 2017;40:22–6.PubMedCrossRef

118.

Walter F, Böckle D, Schmidt-Hegemann N-S, Köpple R, Gerum S, Boeck S, et al. Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. Radiat Oncol. 2018;13:93.PubMedPubMedCentralCrossRef

119.

Zeng Y, Liang W, He J. Esophageal cancer in elderly patients: a population-based study [Internet]. J Clin Oncol. 2017:e15561–1. Available from:. https://doi.org/10.1200/jco.2017.35.15_suppl.e15561.

120.

Jain R, Yee J-L, Shaikh T, Au C, Handorf E, Meyer JE, et al. Treatment-related toxicity and outcomes in older versus younger patients with esophageal cancer treated with neoadjuvant chemoradiation. J Geriatr Oncol. 2020;11:668–74.PubMedCrossRef

121.

Song EY, Frakes JM, Extermann M, Klocksieben F, Mehta R, Saeed S, et al. Clinical factors and outcomes of octogenarians receiving curative surgery for esophageal cancer. J Surg Res. 2020;251:100–6.PubMedCrossRef

122.

Ruol A, Portale G, Castoro C, Merigliano S, Cavallin F, Battaglia G, et al. Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg. 2007;32:445–8.PubMedCrossRef

123.

Moreno AC, Verma V, Hofstetter WL, Lin SH. Patterns of care and treatment outcomes of elderly patients with stage I esophageal cancer: analysis of the National Cancer Data Base. J Thorac Oncol. 2017;12:1152–60.PubMedCrossRef

124.

Vlacich G, Samson PP, Perkins SM, Roach MC, Parikh PJ, Bradley JD, et al. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database. Cancer Med. 2017;6:2886–96.PubMedPubMedCentralCrossRef

125.

Zhao Q, Hu G, Xiao W, Chen Y, Shen M, Tang Q, et al. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: a retrospective cohort study. Medicine. 2017;96:e7920.PubMedPubMedCentralCrossRef

126.

Chen M, Liu X, Han C, Wang X, Zhao Y, Pang Q, et al. Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A). BMC Cancer BioMed Central. 2020;20:1–9.

127.

Fawaz ZS, Kazandjian S, Tsui JM, Devic DS, Lecavalier-Barsoum M, Vuong T, et al. What is the optimal radiation technique for esophageal cancer? A dosimetric comparison of four techniques. Cureus. 2018;10:e2985.PubMedPubMedCentral

128.

Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.PubMedCrossRef

129.

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.PubMedCrossRef

130.

Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state—separating truth from wishful thinking [Internet]. Nat Rev Clin Oncol. 2014:549–57. Available from:. https://doi.org/10.1038/nrclinonc.2014.96.

131.

Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature [Internet]. Lung Cancer. 2013:197–203. Available from:. https://doi.org/10.1016/j.lungcan.2013.07.026.

132.

Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PLoS One. 2018;13:e0195149.PubMedPubMedCentralCrossRef

133.

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.PubMedCrossRef

Titel: The Role of Radiation Therapy in the Older Patient
verfasst von: Ammoren Dohm
Roberto Diaz
Ronica H. Nanda
Publikationsdatum: 01.01.2021
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 1/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-020-01000-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Role of Radiation Therapy in the Older Patient

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Management of the Neck in Well-Differentiated Thyroid Cancer

How to Measure Pain

Vitamin D in Head and Neck Cancer: a Systematic Review

Advances in the Management of Pediatric Sarcomas

Receptor for Advanced Glycation End Products (RAGE) and Its Polymorphic Variants as Predictive Diagnostic and Prognostic Markers of NSCLCs: a Perspective

Considerations in Surgical Management of Gastrointestinal Cancer in Older Patients

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie